SITE012-0252

SITE012 (BRA) › SITE012-0252

SITE012-0252

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2026-06-18

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-11 (study day 41); relationship: not assessed

severe assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 40); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.